QCOR News 91.27 06/30/2014 05:21:55 Questcor Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 91.27 $QCOR

Questcor Pharmaceuticals Up 35.0% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Fri Jun 27, 11:09AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 34.95% as of today's recent price of $90.97.

Why Small-Cap Stocks ARRIS and Questcor Have Huge Growth Potential
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jun 26, 4:45PM CDT
Source: ARRIS. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap stocks to your portfolio but don't have the time or expertise to hand-pick a few, the  Vanguard...

Look for Shares of Questcor Pharmaceuticals to Potentially Rebound after Yesterday's 1.50% Sell Off
Comtex SmarTrend(R) - Thu Jun 26, 4:27PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $90.01 to a high of $92.20. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $91.08 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Questcor Pharmaceuticals Closes Transaction to Acquire International Rights to Synacthen® and Synacthen® Depot
PR Newswire - Mon Jun 23, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the transaction acquiring rights to Synacthen® and Synacthen® Depot from Novartis Pharma AG and Novartis AG in certain countries outside the U.S. has now closed. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin peptide. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for multiple indications, including certain autoimmune and inflammatory conditions as well as for diagnostic use, but have never been developed or approved for patients in the U.S. Questcor is presently engaged in pre-clinical development for Synacthen in the U.S.

Shares of QCOR Up 38.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 3 months, Questcor Pharmaceuticals has returned 37.98% as of today's recent price of $93.01.

Look for Shares of Questcor Pharmaceuticals to Potentially Pullback after Yesterday's 2.84% Rise
Comtex SmarTrend(R) - Tue Jun 17, 4:56PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.15 to a high of $91.68. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $90.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 32.3% (QCOR)
Comtex SmarTrend(R) - Fri Jun 13, 9:09AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 32.27% as of today's recent price of $89.16.

FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna
PR Newswire - Wed Jun 11, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), UnitedHealth Group Inc. (NYSE: UNH), GW Pharmaceuticals PLC (NASDAQ: GWPH), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3590-100free.

Shares of QCOR Up 29.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 4:46PM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 29.45% as of today's recent price of $87.26.

Lannett Tops Trio Of Medical Small Cap Leaders
at Investor's Business Daily - Thu Jun 05, 7:02AM CDT
Small, fast-growing companies in hot industries, such as generics drugmaker Lannett, are good prospects for a stock watch list. Today's Screen Of The Day is Small Cap Leaders, highly rated companies with a market capitalization of $300 million to $2...

Pharma Stocks Review -- Research on Akorn, Questcor Pharma, Nektar Therapeutics, and Endocyte
PR Newswire - Thu Jun 05, 7:00AM CDT
On Wednesday, June 04, 2014, the NASDAQ Composite ended at 4,251.64, up 0.41%, the Dow Jones Industrial Average advanced 0.09%, to finish the day at 16,737.53, and the S&P 500 closed at 1,927.88, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.30, up 0.23%, with the index also advancing 3.81% in the last one month. Investor-Edge has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Nektar Therapeutics (NASDAQ: NKTR) and Endocyte Inc. (NASDAQ: ECYT). Free technical research on AKRX, QCOR, NKTR and ECYT can be downloaded upon signing up at:

Questcor Provides Support to Lupus Foundation of America Awareness, Education and Advocacy Efforts
PR Newswire - Tue Jun 03, 9:28AM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its sponsorship of the Lupus Foundation of America's (LFA) eight national office Walk to End Lupus Now(TM) events and its support of a variety of Lupus Awareness Month activities.

FDA Approvals, Digital Health Guidance, Conference Presentations, and Recognitions - Analyst Notes on Intercept Pharmaceuticals, Cigna, Baxter, Questcor and Mallinckrodt
PR Newswire - Tue Jun 03, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), Cigna Corporation (NYSE: CI), Baxter International Inc. (NYSE: BAX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) and Mallinckrodt PLC (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3242-100free.

SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.43% Gain
Comtex SmarTrend(R) - Mon Jun 02, 4:25PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $89.51 to a high of $92.38. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $90.50 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...

Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Wed May 28, 5:39PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.75 to a high of $90.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.75 on volume of 702,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Questcor Receives "Recognition of Appreciation" Award from MS Views & News
PR Newswire - Wed May 28, 2:28PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization.

Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 86

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 78

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 81

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 99

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 50

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 16

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 55

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 17

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

Vizzy Hard Seltzer Unveils Exciting Cream Pop Variety Pack

Updated Category News Views 247

Vizzy Hard Seltzer Expands Flavor Options with New Variety Pack Vizzy Hard Seltzer is making waves by introducing its delightful Cream Pop Variety Pack, which marks a new chapter in its product line. This exciting pack is all set to enhance your sipping experience with flavors inspired by cherished childhood treats. Bringing together the well-loved Orange Cream Pop and...

Continue Reading
X-Bow Systems Expands DoD Partnership with New Funding Boost

Updated Category News Views 406

Significant Funding Boost for X-Bow Systems X-Bow Systems Inc. is making waves in the defense industry with its recent expansion of a crucial contract with the Department of Defense (DoD). This boost in funding follows a notable $64 million awarded in 2023 aimed at enhancing the production capacity of solid rocket motors. With this additional investment, X-Bow aims to...

Continue Reading
Digerati Technologies Mourns the Loss of Founding CEO Arthur Smith

Updated Category News Views 211

A Tribute to CEO Arthur L. Smith of Digerati Technologies Digerati Technologies, Inc. (OTC: DTGI), known for its dedicated approach to cloud services, recently lost its revered Founder and Chief Executive Officer, Arthur L. Smith. His passing has left a profound impact on the company, its employees, and the broader business community. Honoring a Visionary Leader Arthur L....

Continue Reading
Investors Encouraged to Engage in Transocean Ltd. Lawsuit

Updated Category News Views 142

Opportunity for Transocean Ltd. Investors Recent developments have opened a new chapter for investors of Transocean Ltd. (NYSE: RIG). Those who purchased securities between October 31, 2023, and September 2, 2024, referred to as the "Class Period," are now being called to action. This is a moment not just for individual investors, but a collective initiative to ensure...

Continue Reading
Blue Owl Capital Sets New Milestones with OWL Stock Growth

Updated Category News Views 144

Blue Owl Capital's Remarkable Stock Surge In a noteworthy display of market confidence, OWL stock has reached an impressive price level of $23.7, marking an all-time high. This significant milestone highlights the company's strong performance and the optimistic outlook investors have regarding its potential for growth. Over the last year, the company has experienced an...

Continue Reading